Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary

Valeritas Holdings VLRX shares are trading higher after the company on Tuesday afternoon announced its V-Go wearable insulin device has been adopted on multiple managed care formularies.

The V-Go is a disposable device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes, thereby providing an alternative to taking multiple daily insulin injections.

Valeritas shares were trading up 36% at $4 in Wednesday’s pre-market session. The stock has a 52-week high of $34 and a 52-week low of $2.10.

Related Links:

Amneal Announces Restructuring Plan, Cuts Guidance

Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!